Is Pseudomonas Pneumonia Truly Exceptional? Re-evaluating the Standard of Practice

Pseudomonas aeruginosa is a notorious cause of hospital- and ventilator-acquired pneumonia (HAP/VAP) (1). Whereas guidelines generally recommend monotherapy and shorter treatment duration for HAP/VAP (1), many experts advocate for a distinct approach when P. aeruginosa is involved, especially in septic shock (1-3,7). This post examines the evidence behind this “exceptionalism”, addressing the following questions:

1. How to empirically treat Pseudomonas Pneumonia?

2. Should combination therapy be used in definitive treatment of Pseudomonas pneumonia?

3. Is there any evidence to treat Pseudomonas pneumonia longer than 7 days?

1. How to empirically treat Pseudomonas Pneumonia?

 

As it goes for empirical treatment, answering the when is as important as the how.

When to cover for Pseudomonas aeruginosa?

The decision to cover for P. aeruginosa empirically depends on two factors: the local prevalence of the pathogen and the severity of the disease (4).

Although P. aeruginosa is responsible for 4 to 5% of all community-acquired pneumonias (CAP) in some observational studies (5), empiric treatment for all CAP cases offers limited benefit. One meta-analysis, for instance, reported a mortality benefit of just 0.12% (4). By contrast, the absolute risk reduction of empiric coverage of P. aeruginosa increased to 1.1% in septic shock and up to 2.4% in HAP/VAP (4). Moreover, Pseudomonas pneumonia is more common in intensive care patients and those with chronic pulmonary co-morbidities such as severe COPD, history of tracheostomy and bronchiectasis (6). Additionally, a positive sputum Gram-stain for gram-negative rods and certain CT abnormalities (in particular thick-walled cavities with irregular walls in the right-upper lobe) can raise suspicion for Pseudomonas pneumonia (6).

How to cover for Pseudomonas aeruginosa?

As P. aeruginosa possesses a multitude of intrinsic resistance mechanisms, only a handful of antibiotic classes are available for treatment. These options are further limited nowadays due to the presence of widespread resistance. For instance, 31% of P. aeruginosa strains in Europe were resistant to at least one antimicrobial class in 2021 and 18% were resistant to more than 2 classes (8). Furthermore, the risk for new resistance development is cumulative with each day of any anti-pseudomonal antibiotic exposure (9). Whereas some authors recommend avoiding carbapenems as empirical therapy (10) as they seemed the most potent selectors of resistance in some studies (9,11), a large, retrospective cohort study including 7118 critically-ill patients clearly demonstrated the time-dependent nature of resistance selection by any anti-pseudomonal beta-lactam antibiotic (9).

Is empirical combination therapy for Pseudomonas pneumonia justified?

Due to widespread resistance, some guidelines recommend empirical combination therapy to increase the likelihood of appropriate coverage of P. aeruginosa (1). Retrospective studies have observed that combination therapy reduces inappropriate empirical therapy and thus lower mortality (11, 12). However, several critical notes must be considered:

I. The latest meta-analysis found no mortality difference between empirical monotherapy and combination therapy for P. aeruginosa bloodstream infections or pneumonia (13). In total, this analysis encompassed 14 studies, including three prospective studies and one randomized controlled trial. Besides the inherent limitations of observational research, nearly half of the studies were over 20 years old, from a period when antimicrobial resistance rates were significantly lower (13).

II. The most commonly proposed combination is adding an aminoglycoside or fluoroquinolone to the beta-lactam backbone(14,18). However, co-resistance is common, casting doubts on the added benefit of a second antibiotic agent (2). For instance, in a study with 1783 multidrug-resistant P. aeruginosa strains, only administering ceftolozane-tazobactam significantly reduced the rate of inappropriate empirical therapy (14). Furthermore, aminoglycoside monotherapy is not recommended as no dosing regimen ensures predictable bacterial killing (15).

III. Another indication for combination therapy in the European guidelines for HAP/VAP is septic shock (1). This recommendation likely reflects the publication date - see also the Surviving Sepsis Campaign guidelines from 2016 (16) - rather than robust evidence. The updated Surviving Sepsis Campaign guidelines of 2021, for instance, recommend against double gram-negative coverage except for patients at high risk for multidrug-resistant organisms (17).

My view:

Effective empirical treatment for Pseudomonas pneumonia depends on understanding local epidemiology: both how frequently P. aeruginosa causes pneumonia and the resistance profiles of local strains. Based on this knowledge, a local empirical antipseudomonal regimen should be selected, whether monotherapy or combination therapy, to ensure coverage of over 90% of all local strains.

2. Should combination therapy be used in definitive treatment of Pseudomonas pneumonia?

Most guidelines have moved away from combination therapy, except for severe, resistant cases as long as appropriate monotherapy is available (1,3). The main arguments against combination therapy as definitive therapy are as follows:

• A meta-analysis showed similar 30-day mortality for targeted monotherapy and combination therapy (13). The in vitro synergistic effect between beta-lactams and other antimicrobial classes was not demonstrated (13). Moreover, the largest retrospective cohort study, which included many critically ill and immunocompromised patients, found no benefit for combination therapy when monotherapy was guided by susceptibility testing(18).

• 
  

• Combination therapy does not prevent development of resistance (11). In a meta-analysis, emergence of resistance was similar between monotherapy and combination therapy, though superinfections were more common with combination therapy (10).

3. Is there any evidence to treat Pseudomonas pneumonia longer than 7 days?

This remains one of the most debated topics. While both American and European guidelines recommend 7 days of antibiotic therapy for HAP/VAP (1,19), a more recent randomized controlled trial failed to demonstrate the non-inferiority of 7 days compared to 14 days (20).

The evidence:

1. PneumA trial, a randomized, open-label (from day 8) controlled trial from 2003, compared the clinical effectiveness of 8 versus 15 days of antibiotic therapy for VAP (21). Subgroup analysis of non-fermenting gram-negative bacilli (primarily P. aeruginosa) found no difference in mortality or other patient-centered outcomes between the two groups. However, pulmonary infections recurred more often in the shorter-treatment group, resulting in an inability to establish non-inferiority for these pathogens (21).

2. The iDIAPSON trial, published in 2022, was another open-label, randomized trial that specifically compared 8 versus 15 days of antibiotic therapy for P. aeruginosa VAP (20). Again, no differences were found in mortality, duration of mechanical ventilation or length of ICU stay. However, the short-course group experienced twice the risk of VAP recurrence.

Before concluding that longer treatment duration is necessary for Pseudomonas pneumonia, several critical notes:

a. VAP is a major cause of mortality and morbidity in the ICU (20-21): even excluding inappropriate empirical treatment, attributable mortality is estimated at 13.5% (12). It is notable that both studies found no differences in clinically relevant outcomes. Similarly, in a meta-analysis of all randomized trials no difference in these outcomes was observed (22).

b. The disparity between higher VAP recurrence and similar patient-centered outcomes is more likely due to biases in both trials (23). First, short-course patients were at risk for VAP for significantly longer after antibiotic discontinuation. In the PneumA trail, the difference in the median time at risk was 7 days; in iDIAPSON it was 10 days (23). Additionally, both studies were unblinded after discontinuing antibiotics, introducing potential ascertainment bias in recurrence assessment (23). Distinguishing VAP from atelectasis, thromboembolism or other sources of fever remains, after all, challenging (23).

c. A clinically relevant difference between 8 and 15 days of antibiotic therapy for Pseudomonas-induced VAP may still exist. The aforementioned studies are relatively small. Moreover, the iDIAPSON trial is underpowered due to early termination from slow enrollment (20,21).

d. Even among critically ill and immunocompromised patients with multidrug-resistant P. aeruginosa, mortality, 30-day relapse, and other clinically relevant outcomes were found to be similar in one study between shorter (≤8 days) and longer courses (>8 days) of antibiotic therapy (18).

My view:

Currently, there is no convincing evidence that P. aeruginosa HAP/VAP requires prolonged antibiotic treatment, given the associated harm (23) and resistance selection (9). However, more data are needed to resolve this question once and for all.

References:

1. Torres A, Niederman MS, Chastre J, et al. International ERS/ESICM/ESCMID/ALAT guidelines for the management of hospital-acquired pneumonia and ventilator-associated pneumonia: Guidelines for the management of hospital-acquired pneumonia (HAP)/ventilator-associated pneumonia (VAP) of the European Respiratory Society (ERS), European Society of Intensive Care Medicine (ESICM), European Society of Clinical Microbiology and Infectious Diseases (ESCMID) and Asociación Latinoamericana del Tórax (ALAT). Eur Respir J. 2017 Sep 10;50(3):1700582.

2. Zakhour J, Sharara SL, Hindy JR, et al. Antimicrobial Treatment of Pseudomonas aeruginosa Severe Sepsis. Antibiotics (Basel). 2022 Oct 18;11(10):1432.

3. Foucrier A, Dessalle T, Tuffet S, et al. Association between combination antibiotic therapy as opposed as monotherapy and outcomes of ICU patients with Pseudomonas aeruginosa ventilator-associated pneumonia: an ancillary study of the iDIAPASON trial. Crit Care. 2023 May 30;27(1):211.

4. Hunter CJ, Marhoffer EA, Holleck JL, et al. Effect of empiric antibiotics against Pseudomonas aeruginosa on mortality in hospitalized patients: a systematic review and meta-analysis. J Antimicrob Chemother. 2025 Feb 3;80(2):322-333.

5. Torres A, Niederman MS. Too Much or Too Little Empiric Treatment for Pseudomonas aeruginosa in Community-acquired Pneumonia? Ann Am Thorac Soc. 2021 Sep;18(9):1456-1458.

6. Zhang J, Xie M, Ni R, et al. Community-Acquired Severe Pseudomonas Aeruginosa pneumonia: A Case Report and Review of the Literature. Infect Drug Resist. 2025 Nov 26;18:6185-6190.

7. Marino A, Augello E, Bellanca CM, et al. Antibiotic Therapy Duration for Multidrug-Resistant Gram-Negative Bacterial Infections: An Evidence-Based Review. Int J Mol Sci. 2025 Jul 18;26(14):6905.

8. Antimicrobial resistance surveillance in Europe 2023 - 2021 data. Stockholm: European Centre for Disease Prevention and Control and World Health Organization; 2023.

9. Teshome BF, Vouri SM, Hampton N, et al. Duration of Exposure to Antipseudomonal β-Lactam Antibiotics in the Critically Ill and Development of New Resistance. Pharmacotherapy. 2019 Mar;39(3):261-270.10. Mokrani D, Chommeloux J, Pineton de Chambrun M, et al. Antibiotic stewardship in the ICU: time to shift into overdrive. Ann Intensive Care. 2023 May 6;13(1):39.

11. Yusuf E, Van Herendael B, Verbrugghe W, et al. Emergence of antimicrobial resistance to Pseudomonas aeruginosa in the intensive care unit: association with the duration of antibiotic exposure and mode of administration. Ann Intensive Care. 2017 Dec;7(1):72.

12. Garnacho-Montero J, Sa-Borges M, Sole-Violan J, et al. Optimal management therapy for Pseudomonas aeruginosa ventilator-associated pneumonia: an observational, multicenter study comparing monotherapy with combination antibiotic therapy. Crit Care Med. 2007 Aug;35(8):1888-95.

13. Onorato L, Macera M, Calò F, et al. Beta-lactam monotherapy or combination therapy for bloodstream infections or pneumonia due to Pseudomonas aeruginosa: a meta-analysis. Int J Antimicrob Agents. 2022 Mar;59(3):106512.

14. Moise PA, Gonzalez M, Alekseeva I, et al. Collective assessment of antimicrobial susceptibility among the most common Gram-negative respiratory pathogens driving therapy in the ICU. JAC Antimicrob Resist. 2021 Feb 19;3(1):dlaa129.

15. Rademacher J, Ewig S, Grabein B, et al. Key summary of German national guideline for adult patients with nosocomial pneumonia- Update 2024 Funding number at the Federal Joint Committee (G-BA): 01VSF22007. Infection. 2024 Dec;52(6):2531-2545.

16. Rhodes A, Evans LE, Alhazzani W, et al. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016. Intensive Care Med. 2017 Mar;43(3):304-377.

17. Evans L, Rhodes A, Alhazzani W, et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021. Intensive Care Med. 2021 Nov;47(11):1181-1247.

18. Truong CN, Chin-Beckford N, Vega A, et al. Duration of antibiotic therapy for multidrug resistant Pseudomonas aeruginosa pneumonia: is shorter truly better? BMC Infect Dis. 2024 Sep 3;24(1):911.

19. Kalil AC, Metersky ML, Klompas M, et al. Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clin Infect Dis. 2016 Sep 1;63(5):e61-e111.

20. Bouglé A, Tuffet S, Federici L, et al. Correction to: Comparison of 8 versus 15 days of antibiotic therapy for Pseudomonas aeruginosa ventilator-associated pneumonia in adults: a randomized, controlled, open-label trial. Intensive Care Med. 2022 Jul;48(7):992-994.

21. Chastre J, Wolff M, Fagon JY, et al. Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial. JAMA. 2003 Nov 19;290(19):2588-98.

22. Daghmouri MA, Dudoignon E, Chaouch MA, et al. Comparison of a short versus long-course antibiotic therapy for ventilator-associated pneumonia: a systematic review and meta-analysis of randomized controlled trials. EClinicalMedicine. 2023 Mar 1;58:101880.

23. Metersky ML, Klompas M, Kalil AC. Less Is More: A 7-Day Course of Antibiotics Is the Evidence-Based Treatment for Pseudomonas aeruginosa Ventilator-Associated Pneumonia. Clin Infect Dis. 2023 Feb 18;76(4):750-752.